206 related articles for article (PubMed ID: 25457019)
1. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
2. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
3. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
4. MET inhibitors: translating from bench to bedside.
Mayor S
Lancet Oncol; 2011 Jan; 12(1):14. PubMed ID: 21249721
[No Abstract] [Full Text] [Related]
5. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
6. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
[No Abstract] [Full Text] [Related]
7. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in Xp11 translocation renal cell carcinoma.
Gomolčáková J; Brezinová B; Dubovan P; Jurišová S; Rejlekova K; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2021; 34(2):137-140. PubMed ID: 33906362
[TBL] [Abstract][Full Text] [Related]
9. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
[No Abstract] [Full Text] [Related]
10. Tivantinib (ARQ197) in hepatocellular carcinoma.
Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
Front Immunol; 2021; 12():731527. PubMed ID: 34804015
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
[TBL] [Abstract][Full Text] [Related]
13. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Diamond JR; Salgia R; Varella-Garcia M; Kanteti R; LoRusso PM; Clark JW; Xu LG; Wilner K; Eckhardt SG; Ching KA; Lira ME; Schoenmakers EF; Christensen JG; Camidge DR
J Clin Oncol; 2013 Jun; 31(16):e254-8. PubMed ID: 23610116
[No Abstract] [Full Text] [Related]
14. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
[TBL] [Abstract][Full Text] [Related]
15. Tivantinib in hepatocellular carcinoma.
Trojan J; Zeuzem S
Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
[TBL] [Abstract][Full Text] [Related]
17. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
[TBL] [Abstract][Full Text] [Related]
18. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
19. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
